Date: 2015-09-01
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: MedImmune (USA - global biologics arm of AstraZeneca (UK)
Product: MEDI9197
Action
mechanism: toll-like receptor (TLR) agonist. TLR agonists are promising agents that activate antigen presenting cells such as dendritic cells, enhancing the visibility of a tumor to the immune system. MEDI9197 is a TLR 7/8 agonist. It has been designed to activate a broad range of innate immune cells through targeting of both TLR 7 and 8, leading to a more robust adaptive immune response. A TLR7 and 8 dual agonist can additionally convert immune suppressive cells in the tumor to those with anti-tumor properties, allowing the generation of an effective anti-tumor response. MEDI9197 will also be the first dual TLR7and 8 agonist administered directly into a tumor in a clinical setting. Preclinical studies demonstrate that intratumoral dosing of MEDI9197 may inhibit tumor growth of both the injected and distant lesions in multiple types of cancer, including melanoma. MEDI9197 is uniquely designed for intratumoral injection, allowing the compound to be retained in the tumor and provide specific immune activation, enhancing its safety and tolerability profile.
Disease: solid tumors
Therapeutic area: Cancer - Oncology
Country: USA
Trial
details: This phase I study will evaluate MEDI9197 when administered by intratumoral injection to subjects with solid tumor cancers. (NCT02556463)
Latest news:
